Reference

Ciclesonide for the treatment of asthma

All Rights Reserved. Ciclesonide for the treatment of asthma. Dahl, Ronald (Respiratory Medicine and Allergology, Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Den.). Therapeutics and Clinical Risk Management, 2(1), 25-37 (English) 2006 Dove Medical Press (NZ) Ltd. CODEN: TCRMA6. ISSN: 1176-6336. DOCUMENT TYPE: Journal; General Review CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 1 A review. Ciclesonide is a nonhalogenated corticosteroid that is converted to its clin. active metabolite, desisobutyryl-ciclesonide, by esterases in the airways. Pharmacodynamic studies have shown that inhaled ciclesonide has potent antiinflammatory activity in patients with asthma, and does not appear to have clin. relevant systemic effects, even at high doses. It is highly protein-bound and rapidly metabolized by the liver, and thus has a low oral bioavailability. Ciclesonide is formulated as a soln. for inhalation using a hydrofluoroalkane pressurized metered-dose inhaler. This formulation delivers a high fraction of respirable particles that yield high lung deposition with even distribution throughout the lungs and minimal oropharyngeal deposition. Results from numerous 12-wk trials in patients (including children) with varying degrees of asthma show that morning or evening dosing with ciclesonide is more effective than placebo, and at least equiv. to other inhaled corticosteroids such as budesonide and fluticasone, with regard to improved spirometry, symptom scores, and less need for rescue medication. Results with once-daily ciclesonide are similar to those with twice-daily budesonide or fluticasone. At the dosages used in clin. trials, ciclesonide did not exert any untoward adverse effects and did not affect cortisol prodn. The favorable pharmacol. properties of ciclesonide help explain the low incidence of adverse events, which are mostly mild to moderate in nature. 161115-59-9 and 126544-47-6 are just another two chemicals used in this study. Once-daily ciclesonide offers an efficacious treatment option for stepwise asthma management when inhaled corticosteroids are required. .

Inhalation compositions containing buffers and anti-inflammatory agents

Inhalation compositions containing buffers and anti-inflammatory agents. Banerjee, Partha S.; Malladi, Ramana R.; Chaudry, Imtiaz A. (Dey, L.P., USA). U.S. Pat. Appl. Publ. US 2004023935 A1 5 Feb 2004, 15 pp. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-58. ICS: A61K031-573. NCL: 514174000; 514179000. APPLICATION: US 2002-212573 2 Aug 2002. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Bronchodilating concs. and dild. compns., methods of use thereof, and processes for making the concs. 9004-32-4 and 126544-47-6 are cas registry numbers of chemicals which are used as reagents here. and dild. compns., are provided. The compns. are intended for administration as a nebulized aerosol. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compns. provided herein are also provided. Thus, a compn. contained Fluticasone propionate 150 mg/mL, TPGS 4, propylene glycol 1.67, glycerin 2, NaCl 0.1, and water 92.1% by wt., and buffer 2 mM. .